On ECHEMI
Home > Drugs > Jiangsu Nhwa Pharmaceutical Co., Ltd.

Jiangsu Nhwa Pharmaceutical Co., Ltd.

  • Founded in:

    1999-03-29
  • Country:

    China China
  • Address:

    No. 18, Yangshan Road, Xuzhou Economic and Technological Development Zone
  • Tax NO.:

    913203001363846728
  • Registered Funds:

    1016.176792 million yuan
  • Website:

  • Email:

Related Drugs
Levamisole Hydrochloride Tablets
The main ingredient of this product is: Levamisole hydrochloride. Its chemical name is: (S)-(-)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride.
Name Description Content CAS NO. Registered Holders
Levamisole hydrochloride

It selectively inhibits succinate dehydrogenase in the muscles of the worm, affects the anaerobic metabolism of the worm muscles, and reduces energy production; it depolarizes the nerve muscles, causing continuous muscle contraction and paralysis; its cholinergic effect is beneficial to the excretion of the worm; it may have an inhibitory effect on the microtubule structure of the worm; it has immune regulation and immune preparation functions.

More

It selectively inhibits succinate dehydrogenase in the muscles of the worm, affects the anaerobic metabolism of the worm muscles, and reduces energy production; it depolarizes the nerve muscles, causing continuous muscle contraction and paralysis; its cholinergic effect is beneficial to the excretion of the worm; it may have an inhibitory effect on the microtubule structure of the worm; it has immune regulation and immune preparation functions.

16595-80-5 7
Cilostazol Tablets
The main ingredient of this product is cilostazol, and its chemical name is: 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolone
Name Description Content CAS NO. Registered Holders
Cilostazol

This product and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors (PDEIII inhibitors), which can reduce the degradation of cAMP by inhibiting the activity of phosphodiesterase, thereby increasing the cAMP level in platelets and blood vessels, inhibiting platelet aggregation and vasodilation.

More

This product and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors (PDEIII inhibitors), which can reduce the degradation of cAMP by inhibiting the activity of phosphodiesterase, thereby increasing the cAMP level in platelets and blood vessels, inhibiting platelet aggregation and vasodilation.

73963-72-1 30
Fluconazole Capsules
The main ingredient of this product is fluconazole
Name Description Content CAS NO. Registered Holders
Fluconazole

Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect and can selectively inhibit fungal sterol synthesis. It is effective against Candida infections, Cryptococcus neoformans infections, Malassezia sacchari, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's Chromatids, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes. Studies have shown that taking fluconazole has no effect on male plasma testosterone concentrations or plasma steroid concentrations in women of childbearing age; it has no significant effect on endogenous steroid levels or adrenocorticotropic hormone effects in healthy male volunteers.

More

Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect and can selectively inhibit fungal sterol synthesis. It is effective against Candida infections, Cryptococcus neoformans infections, Malassezia sacchari, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's Chromatids, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes. Studies have shown that taking fluconazole has no effect on male plasma testosterone concentrations or plasma steroid concentrations in women of childbearing age; it has no significant effect on endogenous steroid levels or adrenocorticotropic hormone effects in healthy male volunteers.

86386-73-4 69
Ropivacaine Mesylate Injection
The main component of this product is ropivacaine mesylate, chemical name is (S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinamide methanesulfonate Molecular formula: C17H26N2O.CH3SO3H Molecular weight: 370.51
Name Description Content CAS NO. Registered Holders
Ropivacaine mesylate

It may block the generation and conduction of nerve impulses by increasing the threshold of nerve action potential, delaying the spread of nerve impulses, and reducing the speed of action potential increase. The generation of anesthetic effect is related to the axial diameter, myelination and conduction velocity of nerve fibers.

More

It may block the generation and conduction of nerve impulses by increasing the threshold of nerve action potential, delaying the spread of nerve impulses, and reducing the speed of action potential increase. The generation of anesthetic effect is related to the axial diameter, myelination and conduction velocity of nerve fibers.

854056-07-8 8
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.